PMID- 20584089
OWN - NLM
STAT- MEDLINE
DCOM- 20101105
LR  - 20211020
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Print)
IS  - 0309-0167 (Linking)
VI  - 57
IP  - 1
DP  - 2010 Jul
TI  - Image analysis as an adjunct to manual HER-2 immunohistochemical review: a 
      diagnostic tool to standardize interpretation.
PG  - 27-38
LID - 10.1111/j.1365-2559.2010.03577.x [doi]
AB  - AIMS: Accurate determination of HER-2 status is critical to identify patients for 
      whom trastuzumab treatment will be of benefit. Although the recommended primary 
      method of evaluation is immunohistochemistry, numerous reports of variability in 
      interpretation have raised uncertainty about the reliability of results. Recent 
      guidelines have suggested that image analysis could be an effective tool for 
      achieving consistent interpretation, and this study aimed to assess whether this 
      technology has potential as a diagnostic support tool. METHODS AND RESULTS: 
      Across a cohort of 275 cases, image analysis could accurately classify HER-2 
      status, with 91% agreement between computer-aided classification and the 
      pathology review. Assessment of the continuity of membranous immunoreactivity in 
      addition to intensity of reactivity was critical to distinguish between negative 
      and equivocal cases and enabled image analysis to report a lower referral rate of 
      cases for confirmatory fluorescence in situ hybridization (FISH) testing. An 
      excellent concordance rate of 95% was observed between FISH and the automated 
      review across 136 informative cases. CONCLUSIONS: This study has validated that 
      image analysis can robustly and accurately evaluate HER-2 status in 
      immunohistochemically stained tissue. Based on these findings, image analysis has 
      great potential as a diagnostic support tool for pathologists and biomedical 
      scientists, and may significantly improve the standardization of HER-2 testing by 
      providing a quantitative reference method for interpretation.
FAU - Dobson, Lynne
AU  - Dobson L
AD  - SlidePath Ltd., Swift Square, Northwood Business Park, Santry, Dublin 9, Ireland. 
      lynne.dobson@slidepath.com
FAU - Conway, Catherine
AU  - Conway C
FAU - Hanley, Alan
AU  - Hanley A
FAU - Johnson, Alex
AU  - Johnson A
FAU - Costello, Sean
AU  - Costello S
FAU - O'Grady, Anthony
AU  - O'Grady A
FAU - Connolly, Yvonne
AU  - Connolly Y
FAU - Magee, Hilary
AU  - Magee H
FAU - O'Shea, Daniel
AU  - O'Shea D
FAU - Jeffers, Michael
AU  - Jeffers M
FAU - Kay, Elaine
AU  - Kay E
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
DEP - 20100624
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Algorithms
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers, Tumor/analysis
MH  - Breast Neoplasms/*chemistry/*diagnosis/drug therapy/genetics
MH  - Cohort Studies
MH  - Diagnosis, Computer-Assisted
MH  - Female
MH  - Genes, erbB-2
MH  - Humans
MH  - Image Processing, Computer-Assisted/*methods/standards
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*analysis
MH  - Trastuzumab
PMC - PMC2916223
EDAT- 2010/06/30 06:00
MHDA- 2010/11/06 06:00
CRDT- 2010/06/30 06:00
PHST- 2010/06/30 06:00 [entrez]
PHST- 2010/06/30 06:00 [pubmed]
PHST- 2010/11/06 06:00 [medline]
AID - HIS3577 [pii]
AID - 10.1111/j.1365-2559.2010.03577.x [doi]
PST - ppublish
SO  - Histopathology. 2010 Jul;57(1):27-38. doi: 10.1111/j.1365-2559.2010.03577.x. Epub 
      2010 Jun 24.